Esmolol hydrochloride

Esmolol is an ultra-short acting, cardioselective P-blocker with no intrinsic sympathomimetic activity. The capability of rapid reversal makes esmolol uniquely suitable for the acute management of supraventricular tachycardia and the control of blood pressure and heart rate during surgery or other cardiac emergencies.

Esmolol Hydrochloride is a white to off-white crystalline powder. It is a relatively hydrophilic compound which is very soluble in water and freely soluble in alcohol. Its partition coefficient (octanol/water) at pH 7.0 is 0.42 compared to 17.0 for propranolol.
Esmolol Hydrochloride has the empirical formula C16H26NO4Cl and a molecular weight of 331.8. It has one asymmetric center and exists as an enantiomeric pair.

DuPont Critical Care (USA)

antiarrhytmic;cardioselective beta1 receptor blocker

Cardioselective -adrenergic blocker. Antiarrhythmic

Esmolol hydrochloride is indicated for paroxysmal supraventricular tachycardia, the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Esmolol hydrochloride is also indicated in noncompensatory sinus tachycardia where, in the physician's judgment, the rapid heart rate requires specific intervention. Esmolol hydrochloride is not intended for use in chronic settings where transfer to another agent is anticipated.

ChEBI: The hydrochloride salt of esmolol. A cardioselective and short-acting beta1 receptor blocker with rapid onset but lacking intrinsic sympathomimetic and membrane-stabilising properties, it is used in the management of su raventricular arrhythmias, and for the control of hypertension and tachycardia during surgery.

A solution of 17 g (0.1 mole) of 3-(4-hydroxyphenyl)propionic acid in 500 mL methanol and 2 mL concentrated sulfuric acid were placed in a Soxhlet extractor charged with 3A molecular sieves. The solution was refluxed for 72 hours and the sieve were exchanged at 24 hour intervals. The reaction medium was then evaporated to an oil which was dissolved in 100 mL toluene and extracted with 100 mL water (3 times). The toluene phase was dried over magnesium sulfate, treated with activated charcoal and evaporated to provide 15 g (80%) of a clear oil. The NMR spectrum was consistent with the methyl 3-(4-hydroxyphenyl)propionate.
The oil described above was utilized directly in the condensation reaction with the epichlorohydrin. A mixture of 0.1 mole of methyl 3-(4- hydroxyphenyl)propionate, 0.2 mole potassium carbonate and 0.4 mole epichlorohydrin in 250 mL acetone was heated to reflux for 24 hours. The reaction medium was then filtered and evaporated. The residue was taken up in 100 mL toluene and washed with 100 mL 1.0 N NaOH and 100 mL water (2 times). The toluene phase was then dried over magnesium sulfate and evaporated to provide the crude product as an oil. Purification was effected by vacuum distillation (156°C/0.4 mm) and provided methyl 3-[4-(2,3- epoxypropoxy)phenyl]propionate. The NMR and IR spectra and elemental analysis data were consistent with the assigned structure.
A mixture of 50 g (0.21 mole) of methyl 3-[4-(2,3- epoxypropoxy)phenyl]propionate and 100 mL of isopropylamine in 100 mLmethanol was heated to reflux for 4 hours. The reaction medium was then evaporated and the resulting oil taken up in methanol and treated with ethereal HCl and provided crystals which were recrystallized in similar fashion to provide 28 g (47%) of white crystals: melting point 85-86°C. The NMR and IR spectra and the elemental analysis data were consistent with the structure of methyl 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoate.
In practice it is usually used as hydrochloride.

Brevibloc(Baxter Healthcare).

Beta-adrenergic blocker

Esmolol Hydrochloride is a beta1-selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages. Its elimination half-life after intravenous infusion is approximately 9 minutes. Esmolol Hydrochloride inhibits the beta1 receptors located chiefly in cardiac muscle, but this preferential effect is not absolute and at higher doses it begins to inhibit beta2 receptors located chiefly in the bronchial and vascular musculature.
Esmolol Hydrochloride is rapidly metabolized by hydrolysis of the ester linkage, chiefly by the esterases in the cytosol of red blood cells and not by plasma cholinesterases or red cell membrane acetylcholinesterase. Total body clearance in man was found to be about 20 L/kg/hr, which is greater than cardiac output; thus the metabolism of Esmolol Hydrochloride is not limited by the rate of blood flow to metabolizing tissues such as the liver or affected by hepatic or renal blood flow. Esmolol Hydrochloride has a rapid distribution half-life of about 2 minutes and an elimination half-life of about 9 minutes.

Beta-adrenoceptor blocker
Short-term treatment of supraventricular arrhythmias (including AF, atrial flutter, sinus tachycardia)
Tachycardia and hypertension in the perioperative period

Hypotension (in 20-50% of pts), diaphoresis, pallor, flushing, peripheral ischemia, bradycardia, heart block, heart failure, sudden cardiac death.
Dizziness, confusion, headache, fatigue, anxiety.
Nausea, vomiting, fever.
Bronchospasm, cough, wheeziness, nasal stuffiness.
Urinary retention.
Inflammation and induration at injection site.

Esmolol may be used as test drug to indicate whether beta-blocker therapy is warranted as an antiarrhythmic agent, particularly in cats with hypertrophic cardiomyopathy, or as an infusion in the shortterm treatment of supraventricular tachyarrhythmias (e.g., atrial fibrillation/flutter, sinus tachycardia).

Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: NSAIDs antagonise hypotensive effect.
Anti-arrhythmics: increased risk of myocardial depression and bradycardia; with amiodarone, increased risk of bradycardia and AV block and myocardial depression; increased risk of myocardial depression and bradycardia with flecainide.
Antidepressants: enhanced hypotensive effect with MAOIs.
Antimalarials: increased risk of bradycardia with mefloquine.
Antipsychotics: enhanced hypotensive effect with phenothiazines
Calcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; severe hypotension and heart failure occasionally with nifedipine and possibly other dihydropyridines; asystole, severe hypotension and heart failure with verapamil - avoid concomitant verapamil use.
Antihypertensives: enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers.
Cytotoxics: possible increased risk of bradycardia with crizotinib.
Diuretics: enhanced hypotensive effect.
Fingolimod: possibly increased risk of bradycardia.
Moxisylyte: possible severe postural hypotension.
Sympathomimetics: severe hypertension with adrenaline and noradrenaline and possibly dobutamine

Esmolol hydrochloride is metabolised by esterases into an acid metabolite (ASL-8123) and methanol. This occurs through hydrolysis of the ester group by esterases in the red blood cells. Esmolol hydrochloride is excreted by the kidneys, partly unchanged (less than 2% of the administered amount), partly as acid metabolite that has a weak (less than 0.1% of esmolol) beta-blocking activity. The acid metabolite is also excreted in the urine